Satisfaction of young women with estradiol valerate/dienogest in real clinical practice in Russia: results of prospective multicenter observational study Q-SWAN

BACKGROUND : E2V/DNG is widely use in Russian clinical practice, although satisfaction of Russian patients and doctors has not been ever evaluated and analysed.AIM: To evaluate satisfaction in young women (18–35 years old) with a drug containing estradiol valerate/dienogest (E2V/ DNG) over a 6-month period in real clinical practice in Russia. MATERIALS AND METHODS : This was a prospective multicenter study (Q-SWAN – Qlaira, Satisfaction, WomAN [ClinicalTrials. gov: NCT04901377]) that assessed satisfaction of 504 women (average age is 27.8 years) with the contraceptive containing E2V/DNG. The characteristics of menstrual bleeding, sexual function, women’s decision to continue and satisfaction of doctors with this method of contraception were also assessed. RESULTS : It was found that 98.4% of women and 100% of doctors were “very satisfied” or “satisfied” with this method of contraception, regardless of the presence or absence of AUB. There was a significant decrease in the intensity, duration of menstrual bleeding and pain. Normalization of the parameters of the FSFI questionnaire was observed in most of the patients (89.7%). The contraceptive E2V/DNG was well tolerated by women, and the overall rate of adverse events was 7.1%. Most women (97.8%) decided to continue taking the medication after completing the study. CONCLUSION : The results of the study showed high satisfaction of young Russian women and doctors with the use of E2V/DNG, regardless of the presence or absence of AUB. The medication has a positive effect on the characteristics of bleeding/ cycle control and on the quality of sexual function, therefore, the women demonstrated a high adherence to this method of contraception.